5-Amino-1MQ is a small molecule inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT). Research in animal models suggests that inhibiting NNMT can increase NAD+ levels, boost cellular metabolism, and reduce fat mass without altering food intake.

Abaloparatide is a synthetic peptide analog of parathyroid hormone-related protein (PTHrP) that acts as an anabolic agent for bone. Research and clinical trials demonstrate its ability to significantly increase bone mineral density and reduce the risk of fractures in osteoporotic patients.

ACE-031 is an investigational protein therapeutic designed to build muscle and increase strength by inhibiting signaling through the activin receptor type IIB (ActRIIB). Research primarily focused on its potential to treat muscle-wasting diseases like Duchenne muscular dystrophy, though clinical trials were halted due to safety concerns involving bleeding.

SNAP-8 (Acetyl Octapeptide-3) is a synthetic octapeptide designed as an elongated, more potent version of the popular hexapeptide Argireline. It functions as a topical "Botox-like" peptide by modulating the SNARE complex to reduce the release of acetylcholine, thereby relaxing facial muscles and reducing the depth of expression wrinkles.

Adipotide, also known as FTPP (Fat Targeted Proapoptotic Peptide), is an experimental peptidomimetic designed to induce weight loss by targeting and destroying the blood vessels that supply white adipose (fat) tissue. Research in animal models, including non-human primates, has shown it can cause rapid weight loss and improve insulin resistance by triggering apoptosis in fat-supplying endothelial cells.

Afamelanotide is a synthetic analogue of alpha-melanocyte stimulating hormone (α-MSH) that stimulates melanin production in the skin. It is FDA-approved under the brand name Scenesse to increase pain-free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (EPP). Research also explores its potential in other photosensitivity disorders and vitiligo.

AICAR (Acadesine) is an AMP analog that directly activates AMP-activated protein kinase (AMPK), a master regulator of cellular energy metabolism. Research indicates it can mimic the metabolic effects of exercise, enhancing endurance, increasing fatty acid oxidation, and improving glucose uptake in muscle tissues.

Albiglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist originally developed for the treatment of type 2 diabetes. It works by mimicking the incretin hormone GLP-1, which stimulates insulin release and suppresses glucagon secretion, leading to improved blood sugar control. Although it received FDA approval and demonstrated cardiovascular benefits, it was later discontinued by the manufacturer for commercial reasons rather than safety concerns.

Aleniglipron (GSBR-1290) is an investigational, orally-available, non-peptide small molecule agonist of the GLP-1 receptor. Research indicates it induces insulin release, promotes glucose clearance, reduces food intake, and decreases body weight, offering a potential once-daily oral alternative to injectable GLP-1 therapies for obesity and type 2 diabetes.

Alprostadil is a synthetic form of prostaglandin E1 (PGE1), a naturally occurring vasodilator. It is widely researched and utilized for its ability to relax smooth muscle and expand blood vessels, making it a primary treatment for erectile dysfunction and a critical intervention for maintaining ductus arteriosus patency in neonates with specific heart conditions.

Amycretin is a novel, unimolecular co-agonist that synergistically activates both GLP-1 and amylin receptors. Early clinical research shows it can significantly reduce body weight, with trials demonstrating up to 24% weight loss over 36 weeks.

AOD-9604 is a modified fragment of human growth hormone (HGH) that includes amino acids 177-191. Research indicates it mimics the fat-burning effects of HGH by stimulating lipolysis and inhibiting lipogenesis, without the adverse effects on blood sugar or tissue growth typically associated with full-length HGH.

Apitegromab is a fully human monoclonal antibody designed to selectively inhibit the activation of myostatin, a protein that limits muscle growth. Research shows it has the potential to improve motor function and preserve muscle mass in patients with spinal muscular atrophy (SMA) when used alongside standard therapies.

ARA-290, also known as Cibinetide, is an engineered peptide derived from erythropoietin (EPO) that selectively activates the innate repair receptor (IRR) without stimulating red blood cell production. Research has primarily focused on its potential to reduce inflammation, promote tissue repair, and alleviate neuropathic pain, particularly in conditions like sarcoidosis and diabetic neuropathy.

Argireline, also known as Acetyl Hexapeptide-8, is a synthetic peptide commonly used in topical skincare formulations. Research shows it can reduce the appearance of dynamic wrinkles by interfering with the SNARE protein complex, which limits muscle contractions in a manner similar to, but much milder than, botulinum toxin.

Bimagrumab is a fully human monoclonal antibody that binds to activin type II receptors (ActRIIA and ActRIIB). By blocking the binding of negative regulators of muscle growth like myostatin and activin A, it promotes significant skeletal muscle hypertrophy while simultaneously reducing fat mass. Research has explored its potential for treating muscle-wasting disorders, obesity, and type 2 diabetes.

Bioglutide (NA-931) is an investigational oral small-molecule quadruple receptor agonist targeting GLP-1, GIP, glucagon, and IGF-1 receptors. Currently in Phase 2 clinical trials, it is designed to promote significant weight loss while preserving muscle mass and minimizing common gastrointestinal side effects associated with traditional therapies.

Bivamelagon is an investigational oral small-molecule melanocortin-4 receptor (MC4R) agonist. Research shows it can significantly reduce body mass index (BMI) and improve hunger control in patients with acquired hypothalamic obesity.

Botulinum toxin is a neurotoxic protein produced by the bacterium Clostridium botulinum. In medical and cosmetic research, it is used in highly purified, minute doses to temporarily paralyze muscles, treating conditions ranging from facial wrinkles to severe muscle spasms and chronic migraines.

BPC-157 is a synthetic peptide sequence based on a protective compound naturally found in human gastric juice. Research suggests it has significant regenerative properties, promoting the healing of tendons, ligaments, muscles, and the gastrointestinal tract by accelerating angiogenesis and modulating growth factors.

Brimapitide (AM-111) is a cell-permeable peptide that inhibits the c-Jun N-terminal kinase (JNK) pathway, which is involved in stress-induced cell death. It has been primarily researched as an intratympanic injection for the treatment of acute sensorineural hearing loss. While early trials showed promise in protecting inner ear hair cells from apoptosis, later Phase 3 trials yielded mixed results, though it remains a compound of interest for inner ear neuroprotection.

Cagrilintide is a long-acting amylin analog that mimics the natural hormone amylin to regulate blood sugar and promote satiety. Research shows it significantly reduces body weight and improves glycemic control, especially when combined with GLP-1 receptor agonists like semaglutide.

CagriSema is an investigational combination therapy containing cagrilintide, a long-acting amylin analogue, and semaglutide, a GLP-1 receptor agonist. Research shows this dual-action approach provides synergistic effects on appetite regulation, gastric emptying, and glucose metabolism, leading to greater weight loss and glycemic control than either compound alone.

Carnosine is a naturally occurring dipeptide composed of beta-alanine and histidine, found in high concentrations in skeletal muscle and brain tissue. Research highlights its role as a potent antioxidant, pH buffer, and anti-glycation agent, with studies exploring its benefits for exercise performance, cognitive function, and cellular aging.

Cebranopadol is a novel, first-in-class analgesic that acts as a dual agonist at both the nociceptin/orphanin FQ peptide (NOP) receptor and the µ-opioid receptor (MOP). Research shows it provides potent pain relief across various pain models, including neuropathic and nociceptive pain, with a potentially improved safety profile compared to traditional opioids.

Cerebrolysin is a complex mixture of low-molecular-weight peptides and amino acids derived from purified porcine brain tissue. Research indicates it mimics the action of endogenous neurotrophic factors, promoting neuroprotection, neurogenesis, and synaptic plasticity. It has been extensively studied and utilized in clinical settings for stroke recovery, traumatic brain injury, and neurodegenerative conditions like Alzheimer's disease.

CJC-1295 (no DAC), also known as Modified GRF 1-29, is a synthetic analogue of Growth Hormone-Releasing Hormone (GHRH). It stimulates the pituitary gland to release growth hormone in a pulsatile manner, mimicking the body's natural physiological rhythms. Research indicates it can increase GH and IGF-1 levels, supporting muscle growth, fat loss, and recovery.

CJC-1295 with DAC is a synthetic analogue of growth hormone-releasing hormone (GHRH) designed to increase the secretion of growth hormone and IGF-1. The addition of the Drug Affinity Complex (DAC) allows the peptide to bind to blood albumin, significantly extending its half-life and providing a continuous release of growth hormone over several days.

CJC-1295 and Ipamorelin are frequently combined in research to synergistically stimulate the release of growth hormone. CJC-1295 acts as a growth hormone-releasing hormone (GHRH) analog to increase basal GH levels, while Ipamorelin is a growth hormone secretagogue that induces pulsatile release. Together, they are studied for their potential to enhance muscle growth, fat loss, recovery, and anti-aging effects without significantly elevating cortisol or prolactin.

Cortistatin is a neuropeptide structurally related to somatostatin that exhibits potent anti-inflammatory, immunomodulatory, and neuroprotective properties. Research indicates it can deactivate inflammatory responses and promote immune tolerance, making it a subject of interest for autoimmune and inflammatory conditions.

Cotadutide is an investigational dual agonist of the GLP-1 and glucagon receptors. Research indicates it improves glycemic control, promotes weight loss, and shows significant potential for improving liver health, particularly in conditions like non-alcoholic steatohepatitis (NASH).

CT-388 is a novel, once-weekly dual GLP-1 and GIP receptor agonist currently in clinical development for the treatment of obesity and type 2 diabetes. Early clinical research demonstrates its potential to induce significant weight loss and improve metabolic health by synergistically targeting two key incretin pathways.

Davunetide, also known as NAP, is an 8-amino acid neuroprotective peptide derived from activity-dependent neuroprotective protein (ADNP). Research indicates it interacts with microtubules to maintain cellular structure and function, and it has been investigated in clinical trials for neurodegenerative conditions like progressive supranuclear palsy and schizophrenia.

Dermorphin is a naturally occurring heptapeptide originally isolated from the skin of South American frogs. It acts as a highly potent and selective mu-opioid receptor agonist, demonstrating profound analgesic (pain-relieving) properties in research models. While it shows significantly greater potency than morphine, its clinical use has been limited by typical opioid-related side effects and regulatory restrictions.

Dihexa is an oligopeptide variant derived from angiotensin IV that binds to hepatocyte growth factor (HGF) and its receptor c-Met. Research in animal models suggests it has profound synaptogenic and neurogenic properties, showing potential for improving cognitive function and repairing brain damage in conditions like Alzheimer's disease and traumatic brain injury.

DSIP is a naturally occurring neuropeptide first discovered in 1977, named for its ability to induce slow-wave (delta) sleep in animal models. Research suggests it may act as a broad neuromodulator, potentially influencing sleep architecture, stress responses, and pain perception, though its exact mechanisms remain elusive.

Ecnoglutide (XW003) is a novel, long-acting, cAMP-signaling biased GLP-1 receptor agonist. It is currently in late-stage clinical development for the treatment of type 2 diabetes and obesity, demonstrating significant improvements in glycemic control and substantial weight loss.

Eloralintide (LY3841136) is a novel, long-acting, selective amylin receptor agonist developed by Eli Lilly for the treatment of obesity. Research shows it mimics the natural hormone amylin to reduce appetite, decrease food intake, and promote significant weight loss, primarily through fat mass reduction.

Enlicitide Decanoate (MK-0616, Lipfendra) is a novel, orally bioavailable macrocyclic peptide that acts as a PCSK9 inhibitor. It is designed to lower low-density lipoprotein cholesterol (LDL-C) by preventing PCSK9 from binding to LDL receptors, thereby increasing the clearance of LDL-C from the bloodstream. Clinical trials have shown it can reduce LDL-C by up to 60% when added to statin therapy.

Enobosarm, also known as Ostarine or MK-2866, is a selective androgen receptor modulator (SARM) developed to treat conditions like muscle wasting and osteoporosis. Research shows it can selectively stimulate muscle and bone growth without the severe androgenic side effects on other tissues typically seen with anabolic steroids.

Epitalon is a synthetic tetrapeptide designed to mimic the effects of epithalamin, a natural polypeptide produced in the pineal gland. Research suggests it can activate telomerase, elongate telomeres, regulate melatonin production, and potentially extend lifespan in animal models.

Erythropoietin (EPO) is a glycoprotein hormone that regulates red blood cell production. While primarily known and FDA-approved for treating anemia associated with chronic kidney disease and chemotherapy, research has also uncovered its potent tissue-protective and neuroprotective properties. These secondary effects have made it a subject of ongoing study for conditions like stroke, traumatic brain injury, and neurodegenerative diseases.

Exenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist originally derived from the venom of the Gila monster. It is FDA-approved for the treatment of type 2 diabetes, where it helps regulate blood sugar levels and often induces weight loss. Emerging research is also exploring its potential neuroprotective effects in conditions like Parkinson's disease.

Follistatin is a naturally occurring glycoprotein that binds to and neutralizes members of the TGF-β superfamily, most notably myostatin and activin. By inhibiting myostatin, a protein that restricts muscle growth, follistatin has been heavily researched for its potential to significantly increase muscle mass and strength, making it a target for treating muscle-wasting diseases.

FOXO4-DRI is an engineered peptide designed to selectively induce apoptosis (programmed cell death) in senescent cells. Research in animal models suggests it can clear these 'zombie cells' by disrupting the interaction between the FOXO4 and p53 proteins, potentially reversing signs of aging and restoring tissue function.

GDF-8 (Growth Differentiation Factor 8), commonly known as myostatin, is a protein that naturally inhibits muscle growth. Myostatin inhibitors are compounds designed to block this protein, thereby promoting significant muscle hypertrophy and preventing muscle wasting in various research models.

GH Blend (4X) is a synergistic combination of four peptides designed to maximize growth hormone release and tissue repair. It combines two GH secretagogues (GHRP-2 and Ipamorelin) with a growth hormone-releasing hormone analogue (Tesamorelin) to stimulate the pituitary gland, while Mechano Growth Factor (MGF) promotes localized muscle repair and cellular growth.

GHK-Cu is a naturally occurring copper complex first isolated from human plasma. Research shows it plays a significant role in promoting wound healing, stimulating collagen synthesis, and modulating gene expression to support tissue repair and anti-aging processes.

GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide that stimulates the release of endogenous growth hormone from the pituitary gland. Research shows it can increase appetite, promote muscle growth, and aid in fat loss by mimicking the action of ghrelin.

Glepaglutide is a long-acting glucagon-like peptide-2 (GLP-2) analog developed primarily for the treatment of short bowel syndrome (SBS). Research shows it promotes intestinal growth, increases fluid and nutrient absorption, and may reduce the need for parenteral support in patients with compromised intestinal function.

The GLOW Blend combines three potent regenerative peptides: GHK-Cu for skin elasticity and tissue remodeling, BPC-157 for accelerated healing of tendons and gut mucosa, and TB-500 for cellular migration and systemic recovery. Research suggests this combination synergistically promotes comprehensive tissue repair, anti-aging benefits, and reduced inflammation.

Glucagon-Like Peptide-1 (GLP-1) is an incretin hormone that stimulates insulin secretion, inhibits glucagon release, and slows gastric emptying. Research has led to the development of GLP-1 receptor agonists, which are widely used for managing type 2 diabetes and obesity due to their profound effects on blood sugar regulation and appetite suppression.

Retatrutide is an investigational triple hormone receptor agonist that targets GLP-1, GIP, and glucagon receptors. Clinical trials have shown unprecedented weight loss efficacy, surpassing dual agonists, by combining appetite suppression with increased energy expenditure.

Glutathione is a powerful tripeptide naturally produced in the body, acting as the 'master antioxidant'. Research shows it plays a critical role in neutralizing free radicals, detoxifying harmful compounds, and supporting immune function. Studies are exploring its benefits for skin health, liver function, and mitigating age-related oxidative stress.

Gonadorelin is a synthetic version of gonadotropin-releasing hormone (GnRH). It stimulates the anterior pituitary gland to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn stimulate the gonads to produce testosterone and sperm in males, and estrogen and eggs in females.

GUBamy (GUB014295) is a novel, long-acting dual amylin and calcitonin receptor agonist (DACRA) developed by Gubra and licensed to AbbVie. It represents a mechanistically distinct approach to obesity treatment compared to GLP-1 receptor agonists, showing significant weight loss potential and an 11-day half-life that supports once-weekly dosing.

hCG is a hormone naturally produced during pregnancy that mimics luteinizing hormone (LH) in the body. In research and clinical settings, it is widely used to stimulate testosterone production, preserve fertility, and treat hypogonadism in men, as well as to induce ovulation in women.

Hexarelin is a potent, synthetic hexapeptide and growth hormone secretagogue (GHS) that stimulates the release of growth hormone. Research indicates it is one of the strongest GH-releasing peptides available, offering potential benefits for muscle growth, fat loss, and cardiovascular health without significantly increasing appetite.

HGH 191AA, also known as Somatotropin, is a bio-identical synthetic version of human growth hormone containing exactly 191 amino acids. Research demonstrates its critical role in cellular regeneration, growth, metabolism, and maintaining healthy human tissue throughout the lifespan.

HGH Fragment 176-191 is a modified synthetic peptide derived from amino acids 176-191 of the human growth hormone (HGH) polypeptide. Research indicates it mimics the way natural HGH regulates fat metabolism, stimulating fat breakdown and inhibiting fat formation, but without the adverse effects on blood sugar or cell proliferation seen with unmodified HGH.

Human Menopausal Gonadotropin (HMG) is a medication containing both follicle-stimulating hormone (FSH) and luteinizing hormone (LH), typically extracted from the urine of postmenopausal women. It is widely used in reproductive medicine to stimulate ovulation in women and spermatogenesis in men, often as part of assisted reproductive technologies (ART) or hypogonadism treatments.

Humanin is a naturally occurring micropeptide encoded by the mitochondrial genome. Research indicates it possesses potent cytoprotective and anti-apoptotic properties, helping cells survive under stress. It is widely studied for its potential neuroprotective effects in Alzheimer's disease and its role in metabolic and cardiovascular health.

Ibutamoren (MK-677) is an orally active, non-peptide growth hormone secretagogue that mimics the action of ghrelin. Research shows it can significantly increase levels of growth hormone (GH) and insulin-like growth factor 1 (IGF-1) without affecting cortisol levels, making it a subject of interest for muscle wasting, bone density, and anti-aging.

Icotrokinra (also known as JNJ-2113) is a first-in-class, orally bioavailable macrocyclic peptide that selectively targets and blocks the interleukin-23 (IL-23) receptor. Research and clinical trials have demonstrated its high efficacy in treating moderate-to-severe plaque psoriasis, offering a targeted oral alternative to traditional injectable biologics.

IGF-1 DES (DES(1-3)IGF-1) is a truncated variant of Insulin-like Growth Factor 1 that lacks the first three amino acids at the N-terminus. This structural modification prevents it from binding to IGF-binding proteins (IGFBPs), resulting in a highly potent, fast-acting peptide. Research primarily focuses on its ability to stimulate cellular hyperplasia and localized tissue repair, particularly in skeletal muscle and gut mucosa.

IGF-1 LR3 is a synthetic, modified version of Insulin-like Growth Factor-1 with an extended half-life and increased potency. Research highlights its ability to promote muscle cell hyperplasia (growth of new muscle cells), enhance protein synthesis, and improve recovery by resisting deactivation by IGF-binding proteins.

Insulin is a vital peptide hormone produced by the pancreas that regulates carbohydrate, fat, and protein metabolism. It facilitates the cellular uptake of glucose from the blood, making it essential for energy storage and the clinical management of diabetes.

IO102-IO103 is an investigational therapeutic cancer vaccine designed to target and destroy immunosuppressive cells and tumor cells expressing IDO and PD-L1. Research indicates that when combined with immune checkpoint inhibitors, it can significantly enhance anti-tumor immune responses, particularly in advanced melanoma.

Ipamorelin is a highly selective growth hormone secretagogue and ghrelin receptor agonist. Research indicates it stimulates the pituitary gland to release endogenous growth hormone without significantly elevating cortisol or prolactin levels, making it a primary focus in studies on anti-aging, muscle preservation, and recovery.

Kisspeptin-10 is a potent neuropeptide that acts as an upstream regulator of the hypothalamic-pituitary-gonadal (HPG) axis. Research shows it stimulates the release of gonadotropin-releasing hormone (GnRH), subsequently increasing luteinizing hormone (LH), follicle-stimulating hormone (FSH), and testosterone levels. It is heavily studied for its potential in treating infertility, hypogonadism, and reproductive disorders.

Klotho peptides are derived from the Klotho protein, a naturally occurring enzyme known for its profound anti-aging and renoprotective properties. Research suggests these peptides can mimic the effects of the full-length protein, potentially improving cognitive function, protecting against oxidative stress, and extending lifespan in animal models.

The KLOW Blend is a comprehensive combination of four well-researched peptides: KPV, BPC-157, TB-500, and GHK-Cu. It is designed to synergistically target inflammation, tissue repair, angiogenesis, and cellular regeneration. Research suggests this multi-pathway approach may accelerate healing of muscles, tendons, and skin while modulating immune responses.

KPV (Lys-Pro-Val) is a naturally occurring tripeptide derived from alpha-melanocyte-stimulating hormone (alpha-MSH). Research highlights its potent anti-inflammatory and antimicrobial properties, making it a promising candidate for conditions like inflammatory bowel disease, skin disorders, and wound healing.

Larazotide (also known as AT-1001) is an investigational eight-amino acid peptide designed to regulate tight junctions in the intestinal lining. Research has primarily focused on its potential to treat celiac disease by preventing the paracellular leakage of gluten peptides, thereby reducing the inflammatory immune response.

LIB-01 (Volufralin) is a novel, first-in-class oral drug candidate being developed for the treatment of erectile dysfunction (ED) and premature ejaculation. It works by enhancing melanocortin type-4 receptor (MC4R) signaling in the central nervous system, demonstrating a unique long-lasting effect that can improve erectile function for up to eight weeks after a short dosing period.

Linaclotide is a 14-amino acid synthetic peptide and a potent guanylate cyclase-C (GC-C) agonist. It is FDA-approved for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Research shows it works locally in the gastrointestinal tract to increase fluid secretion and accelerate transit, while also reducing visceral pain.

Lipo Blend (8X) is a comprehensive lipotropic injection combining eight synergistic compounds designed to support fat metabolism, energy production, and liver health. Research indicates that its components, including L-Carnitine, L-Arginine, Methionine, Inositol, Choline, and B vitamins, work together to enhance lipid transport, optimize metabolic pathways, and reduce post-exercise fatigue.

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that shares 97% sequence identity with human GLP-1. It is FDA-approved for the treatment of type 2 diabetes and chronic weight management, working by stimulating insulin secretion, inhibiting glucagon release, and delaying gastric emptying.

LL-37 is the only human cathelicidin antimicrobial peptide, naturally produced by the body's immune cells. Research shows it possesses broad-spectrum antimicrobial properties against bacteria, fungi, and viruses, while also playing a crucial role in immune modulation, reducing inflammation, and accelerating wound healing.

MariTide (AMG 133) is an investigational bispecific molecule developed by Amgen that uniquely combines a glucagon-like peptide-1 (GLP-1) receptor agonist with a gastric inhibitory polypeptide (GIP) receptor antagonist. Unlike other dual-action drugs that activate both receptors, it activates GLP-1 while blocking GIP, which research suggests may lead to significant, sustained weight loss with less frequent dosing.

Palmitoyl pentapeptide-4, originally known as Matrixyl, is a synthetic peptide widely used in cosmetics to stimulate collagen and elastin production. Research shows it can significantly reduce the appearance of fine lines and wrinkles by promoting the synthesis of extracellular matrix components in the skin.

Mazdutide is an investigational dual agonist of the glucagon-like peptide-1 (GLP-1) and glucagon (GCG) receptors. Clinical research indicates it significantly reduces body weight and improves metabolic parameters in individuals with obesity or type 2 diabetes by suppressing appetite and increasing energy expenditure.

Melanotan II is a synthetic analog of the alpha-melanocyte-stimulating hormone (α-MSH). It was originally developed to induce skin pigmentation (tanning) to protect against UV radiation, but research also demonstrated significant effects on sexual arousal and erectile function.

Melanotan-1 is a synthetic analogue of alpha-melanocyte-stimulating hormone (α-MSH) that stimulates melanin production. It is clinically approved (as afamelanotide) to treat erythropoietic protoporphyria (EPP) by providing photoprotection against UV radiation.

MET-097i is an investigational, ultra-long-acting, fully biased GLP-1 receptor agonist designed for once-monthly subcutaneous injection. It utilizes a proprietary HALO™ peptide lipidation technology to achieve a half-life of approximately 380 hours. Early clinical trials show it produces substantial weight loss comparable to weekly GLP-1 agonists, but with the convenience of monthly dosing and potentially without the need for dose titration.

Mechano Growth Factor (MGF) is a splice variant of Insulin-like Growth Factor-1 (IGF-1) that is naturally produced in muscle tissue following mechanical stress or damage. Research indicates it plays a crucial role in muscle repair and growth by activating muscle stem cells (satellite cells). While highly promising in animal models for tissue regeneration and neuroprotection, human clinical trials on administered MGF are currently lacking.

MIC Blend (4X) is a concentrated combination of lipotropic agents—Methionine, Inositol, and Choline. These compounds work synergistically to support lipid metabolism, promote the export of fat from the liver, and enhance cellular energy production. Research indicates that lipotropic nutrients can aid in managing hepatic steatosis and supporting metabolic health, though clinical evidence for significant weight loss as a standalone treatment remains mixed.

Motixafortide is a potent, long-acting CXCR4 antagonist that stimulates the release of hematopoietic stem cells from the bone marrow into the peripheral blood. It is FDA-approved for use in combination with filgrastim to mobilize stem cells for collection and autologous transplantation in patients with multiple myeloma.

MOTS-c is a naturally occurring mitochondrial-derived peptide that plays a key role in regulating metabolic homeostasis and energy production. Research indicates it acts as an 'exercise mimetic' by activating AMPK, improving insulin sensitivity, and enhancing physical performance in animal models.

MVT-602 (formerly TAK-448) is a potent, long-acting kisspeptin receptor (KISS1R) agonist. Research shows it induces a prolonged luteinizing hormone (LH) surge compared to native kisspeptin, making it a promising candidate for treating female reproductive disorders like polycystic ovary syndrome (PCOS) and hypothalamic amenorrhea (HA), as well as for triggering oocyte maturation in in vitro fertilization (IVF).

N-Acetyl Epitalon Amidate is a modified version of the synthetic tetrapeptide Epitalon (Epithalon), featuring an N-terminal acetyl group and a C-terminal primary amide. These modifications are designed to enhance the peptide's stability, bioavailability, and resistance to enzymatic degradation. Like the original Epitalon, it is researched for its potential to activate telomerase, lengthen telomeres, and support cellular longevity and repair.

NAD+ is a critical coenzyme found in every cell of the body, essential for cellular energy production and mitochondrial function. Research shows that NAD+ levels decline with age, and restoring these levels may improve metabolic health, cognitive function, and resilience to age-related diseases.

Nemifitide (INN-00835) is a novel synthetic pentapeptide analog of melanocyte-inhibiting factor (MIF-1). Research indicates it may possess rapid-acting antidepressant properties, showing efficacy in clinical trials for major depressive disorder within days rather than weeks.

Neuropeptide Y (NPY) is a 36-amino acid peptide widely distributed in the central and peripheral nervous systems. Research indicates it plays a crucial role in stress regulation, anxiety reduction, and energy homeostasis, showing significant potential as a therapeutic for post-traumatic stress disorder (PTSD) and anxiety disorders.

Nomlabofusp (formerly CTI-1601) is a novel cell-penetrant peptide-based recombinant fusion protein designed as a frataxin replacement therapy. It aims to deliver human frataxin directly into the mitochondria of cells, addressing the underlying deficiency in patients with Friedreich's ataxia.

Orforglipron is a novel, orally administered, non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist. Research shows it effectively stimulates insulin secretion, delays gastric emptying, and promotes significant weight loss and glycemic control without the strict fasting protocols required by other oral GLP-1s.

OS-01, also known as Peptide 14, is a proprietary senotherapeutic peptide developed to target skin aging at the cellular level. Research indicates it reduces the accumulation of senescent cells, improves skin barrier function, and promotes overall skin rejuvenation and health.

Oveporexton (TAK-861) is a novel, orally available orexin receptor 2 (OX2R)-selective agonist developed for the treatment of Narcolepsy Type 1. Research shows it effectively restores orexin signaling in the brain, significantly improving wakefulness and reducing cataplexy.

Oxytocin is a naturally occurring neuropeptide and peptide hormone produced in the hypothalamus. It plays a crucial role in social bonding, sexual reproduction, childbirth, and the period after childbirth. Research is also exploring its potential benefits for social anxiety, autism spectrum disorder, and stress modulation.

PE-22-28 is a synthetic heptapeptide derived from spadin, a naturally occurring peptide fragment. It acts as a highly selective inhibitor of the TREK-1 potassium channel, demonstrating potent antidepressant-like and neuroprotective effects in preclinical models with a longer duration of action than its parent compound.

PEG-MGF (Pegylated Mechano Growth Factor) is a modified version of an IGF-1 splice variant that promotes muscle repair and growth. The addition of polyethylene glycol (PEG) extends its half-life in the body, allowing for less frequent administration. Research indicates it plays a significant role in activating muscle stem cells (satellite cells) to repair damage and stimulate tissue regeneration.

Pegcetacoplan is a targeted C3 therapy that regulates excessive activation of the complement cascade. It is FDA-approved for paroxysmal nocturnal hemoglobinuria (PNH) and geographic atrophy, demonstrating significant efficacy in reducing hemolysis and slowing retinal lesion growth.

Pemvidutide is a novel dual-agonist peptide targeting both GLP-1 and glucagon receptors. Research indicates it promotes significant weight loss while simultaneously reducing liver fat content, making it a promising candidate for treating obesity and metabolic dysfunction-associated steatohepatitis (MASH).

Petrelintide is an investigational, long-acting amylin analog being developed for chronic weight management. Research shows it promotes satiety, delays gastric emptying, and induces significant weight loss with a favorable gastrointestinal tolerability profile.

Pinealon is a synthetic tripeptide (Glu-Asp-Arg) designed to act as a peptide bioregulator for the brain and central nervous system. Research suggests it interacts directly with DNA to regulate gene expression, offering neuroprotective effects, improving cognitive function, and reducing oxidative stress in brain cells.

PNC-27 is a synthetic peptide designed to target and destroy cancer cells by binding to the HDM-2 protein expressed on their membranes. Research indicates it induces membrane lysis (necrosis) specifically in tumor cells while leaving healthy cells unharmed. It is currently being studied in preclinical models for its potential as a targeted anti-cancer therapeutic.

PP405 is an investigational topical small-molecule and peptide-like compound designed to activate dormant hair follicle stem cells. Research shows it works by inhibiting the mitochondrial pyruvate carrier (MPC), forcing a metabolic shift that stimulates hair follicles to re-enter the growth phase.

Pramlintide is a synthetic analog of human amylin, a hormone co-secreted with insulin by pancreatic beta cells. It is FDA-approved as an adjunct treatment for type 1 and type 2 diabetes to help control postprandial blood glucose levels, delay gastric emptying, and promote satiety.

Prostamax is a synthetic peptide bioregulator developed to target prostate tissue and function. Research suggests it may influence chromatin structural dynamics, reduce inflammation in prostate tissue models, and potentially normalize androgen receptor expression.

PT-141, also known as bremelanotide, is a synthetic peptide analog of alpha-melanocyte-stimulating hormone (α-MSH). It acts as a non-selective agonist of the melanocortin receptors, primarily MC4R, and is FDA-approved for the treatment of generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Research shows it can also induce erections in men, working through the central nervous system rather than the vascular system.

Rapastinel, also known as GLYX-13, is a synthetic tetrapeptide that acts as a rapid-acting antidepressant and cognitive enhancer. It functions as a partial agonist at the glycine site of the NMDA receptor, promoting neuroplasticity without the dissociative side effects typically associated with full NMDA antagonists like ketamine. While it showed significant promise in early clinical trials for major depressive disorder, Phase 3 trials did not meet their primary endpoints, though research continues into its neuroprotective and cognitive benefits.

Ribupatide (also known as HRS9531 or KAI-9531) is an investigational dual GLP-1 and GIP receptor agonist currently in Phase 3 clinical trials. Research demonstrates its potential to induce significant weight loss and improve metabolic markers in individuals with obesity and type 2 diabetes, with both once-weekly injectable and once-daily oral formulations under investigation.

Risuteganib (also known as Luminate) is a synthetic peptide that functions as a broad-spectrum integrin inhibitor. It is primarily researched for its potential to treat retinal diseases such as diabetic macular edema and dry age-related macular degeneration by reducing oxidative stress and regulating angiogenesis.

Rusfertide is an investigational injectable hepcidin mimetic peptide designed to regulate iron metabolism. It is primarily researched for its ability to control red blood cell production in conditions like polycythemia vera by restricting iron availability.

Selank is a synthetic heptapeptide analogue of the naturally occurring immunomodulatory peptide tuftsin. It has been extensively researched for its anxiolytic (anti-anxiety) and nootropic (cognitive-enhancing) properties, showing the ability to reduce stress and improve memory without the sedative side effects typical of traditional anti-anxiety medications.

Semaglutide is a long-acting GLP-1 receptor agonist that mimics the natural incretin hormone GLP-1. Extensive clinical research demonstrates its profound efficacy in improving glycemic control in type 2 diabetes and inducing substantial, sustained weight loss in individuals with obesity.

Semax is a synthetic peptide derived from adrenocorticotropic hormone (ACTH) that has been extensively studied for its neuroprotective and cognitive-enhancing properties. Research indicates it may modulate brain-derived neurotrophic factor (BDNF) and protect neurons from hypoxic damage, making it a subject of interest in stroke recovery and cognitive decline.

Sermorelin is a synthetic peptide consisting of the first 29 amino acids of naturally occurring growth hormone-releasing hormone (GHRH). It stimulates the pituitary gland to naturally produce and release human growth hormone (hGH), making it a subject of research for age-related growth hormone decline, body composition, and vitality.

Setmelanotide is an FDA-approved melanocortin-4 receptor (MC4R) agonist used for chronic weight management in individuals with specific rare genetic disorders of obesity. Research shows it effectively reduces hyperphagia (extreme hunger) and promotes significant weight loss by restoring function in the impaired MC4R pathway.

SLU-PP-332 is a novel investigational compound known as an 'exercise mimetic' that activates estrogen-related receptors (ERRs). Preclinical research indicates it can enhance endurance, increase fat oxidation, and promote weight loss without altering food intake or requiring physical exercise. It is currently being studied for its potential to treat metabolic disorders and muscle wasting conditions.

SS-31, also known as elamipretide, is a mitochondria-targeted peptide that binds to cardiolipin in the inner mitochondrial membrane. It helps restore mitochondrial function, reduce oxidative stress, and improve cellular energy production. Research has heavily focused on its potential for treating heart failure, mitochondrial myopathies, and age-related cellular decline.

Survodutide is an investigational dual agonist of the glucagon and GLP-1 receptors. Research indicates it significantly reduces body weight and improves liver health in conditions like MASH by suppressing appetite and increasing energy expenditure.

Taspoglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist originally developed for the treatment of type 2 diabetes. While it demonstrated significant efficacy in improving glycemic control and promoting weight loss in Phase III clinical trials, its development was ultimately halted due to high incidences of gastrointestinal side effects and hypersensitivity reactions.

Tat-Beclin-1 is a cell-penetrating peptide that potently induces autophagy, the body's cellular recycling process. Research in animal models demonstrates its ability to clear cellular debris, combat infectious diseases, and potentially increase lifespan by promoting cellular health.

TB-500 is a synthetic version of the naturally occurring peptide Thymosin Beta-4. Research indicates it plays a crucial role in tissue repair, wound healing, and reducing inflammation by upregulating actin, a vital protein for cell structure and movement.

Teduglutide is a glucagon-like peptide-2 (GLP-2) analog that promotes the growth and repair of the intestinal lining. It is FDA-approved for the treatment of Short Bowel Syndrome (SBS) in patients who are dependent on parenteral support, helping them reduce or eliminate the need for intravenous fluids and nutrition.

Teriparatide is a recombinant form of parathyroid hormone (PTH 1-34) that stimulates new bone formation. It is FDA-approved for the treatment of osteoporosis in men and women at high risk for fracture, acting as an anabolic agent rather than just an antiresorptive one.

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to secrete growth hormone. It is FDA-approved for reducing excess visceral abdominal fat in HIV-infected patients with lipodystrophy and is being researched for potential cognitive benefits.

Tesofensine is a triple monoamine reuptake inhibitor (serotonin, noradrenaline, and dopamine) originally developed for neurodegenerative diseases. Clinical trials have demonstrated its significant weight loss properties by suppressing appetite and increasing resting energy expenditure.

Thymalin is a thymus-derived polypeptide complex that acts as a broad-spectrum immunomodulator. Research indicates it supports immune function by regulating T-cell differentiation and proliferation, and it has been studied for its potential in treating immunodeficiencies, respiratory infections, and age-related immune decline.

Thymosin Alpha-1 is a naturally occurring peptide produced by the thymus gland that plays a vital role in modulating the immune system. Research demonstrates its ability to enhance T-cell function, improve vaccine response, and support the body's defense against viral infections and certain cancers.

Thymosin Beta-4 is a naturally occurring 43-amino acid peptide that plays a vital role in tissue repair, cell migration, and inflammation reduction. Research highlights its ability to promote angiogenesis and wound healing, making it a subject of study for cardiovascular repair, corneal healing, and muscle recovery.

Tirzepatide is a novel, first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Clinical research demonstrates unprecedented efficacy in improving glycemic control in type 2 diabetes and achieving substantial weight loss in individuals with obesity.

Trevogrumab (also known as REGN1033) is a fully human monoclonal antibody designed to specifically bind and neutralize myostatin, a natural protein that inhibits muscle growth. Research has focused on its potential to treat muscle wasting conditions, sarcopenia, and muscular dystrophies by promoting increases in lean muscle mass.

Triptorelin is a synthetic decapeptide agonist analog of gonadotropin-releasing hormone (GnRH). It initially stimulates but subsequently downregulates pituitary GnRH receptors, leading to a profound suppression of sex hormones. It is widely researched and utilized in clinical settings for hormone-dependent conditions like advanced prostate cancer, endometriosis, and central precocious puberty.

Vasoactive Intestinal Peptide (VIP) is a 28-amino acid neuropeptide that functions as a potent vasodilator, immune regulator, and neurotransmitter. Research highlights its ability to reduce inflammation, regulate immune responses, and improve respiratory and cardiovascular conditions.

Vesugen is a synthetic tripeptide (Lys-Glu-Asp or KED) developed as a blood vessel bioregulator. Research indicates it supports vascular health by improving microcirculation, enhancing endothelial cell function, and potentially mitigating age-related vascular changes like atherosclerosis.

Vilon is a synthetic dipeptide (Lys-Glu) developed by the St. Petersburg Institute of Bioregulation and Gerontology. Research indicates it has strong immunomodulatory properties, stimulating thymus function, enhancing T-cell activity, and showing potential in treating immunodeficiencies and age-related immune decline.

Methylcobalamin is the active, coenzyme form of Vitamin B12 that is essential for cell growth, blood formation, and neurological function. Research shows it plays a critical role in DNA synthesis and myelin formation, making it a highly effective treatment for B12 deficiency, pernicious anemia, and various neuropathies.

VK2735 is an investigational dual agonist of the GLP-1 and GIP receptors developed by Viking Therapeutics. Research shows it significantly reduces body weight and improves metabolic markers in clinical trials, positioning it as a potential next-generation treatment for obesity.

The 'Wolverine Blend' is a popular research combination of two well-known healing peptides: BPC-157 and TB-500 (Thymosin Beta-4). Research suggests that BPC-157 promotes angiogenesis and gastrointestinal healing, while TB-500 upregulates actin, facilitating cell migration and tissue repair. Together, they are studied for their synergistic potential in accelerating recovery from muscle, tendon, and ligament injuries.

Ziconotide, marketed as Prialt, is a synthetic equivalent of a naturally occurring conopeptide found in the venom of the marine cone snail Conus magus. It is a potent, non-opioid analgesic that works by blocking N-type voltage-gated calcium channels in the spinal cord, effectively interrupting pain signal transmission. Research and clinical use have established its efficacy for severe, refractory chronic pain when administered intrathecally.

Zilucoplan is a synthetic, macrocyclic peptide that binds to complement component 5 (C5) and inhibits its cleavage. It is FDA-approved under the brand name Zilbrysq for the treatment of generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody positive, offering a targeted approach to reduce immune-mediated muscle weakness.

Zovaglutide (ZT002) is a novel, ultra-long-acting GLP-1 receptor agonist designed for once-monthly subcutaneous administration. Research indicates it produces clinically meaningful weight loss and cardiometabolic improvements in individuals with overweight or obesity, with a safety profile comparable to existing GLP-1 therapies.